The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in the Rocky Mountain region - an area with a population of approximately eight million people. Over the past five years, the NCI sponsored research portfolio has nearly doubled from $21 million to 39.7 million, excluding the Core grant. Also doubled were the number of subjects accrued to clinical trials and the number of outpatient visits. UCCC is a """"""""matrix"""""""" center within the University of Colorado Denver and Health Sciences Center (UCDHSC) and is currently transitioning to its new campus at Fitzsimons. Its major clinical care centers include the University of Colorado Hospital (UCH), Denver Veterans Administration Medical Center (DVAMC), Denver Health Medical Center (DHMC), and The Children's Hospital Denver (TCH). We also have a growing number of satellite clinics staffed directly by our faculty including Montrose Hospital in Montrose, Valley View Hospital in Glenwood Springs, and Vail Valley Medical Center in Edwards. Others are in development. We have affiliates (CGOPs) including Lutheran Hospital in Wheat Ridge, St. Mary's Hospital in Grand Junction, Memorial Hospital in Colorado Springs, Poudre Valley Medical Center in Fort Collins, and United Medical Center in Cheyenne, Wyoming. Our U10- and UCOP-funded membership in the Southwest Oncology Group (SWOG) fulfills many of the goals of our Cancer Center by providing broad access to innovative phase II and III treatment and chemoprevention trials to the citizens of Colorado. This grant provides partial support for the needed monitoring and oversight to run clinical trials at satellite clinics and affiliates. Our faculty, in turn, have provided strong administrative and scientific leadership, particularly in the GU and Lung Committees and the Surgery, Pathology and Radiation Therapy modalities as documented by serving or chairing SWOG committees, serving as PIs for phase ll/lll SWOG group trials including PCPT and SELECT, conducting pilots to provide the basis for subsequent SWOG trials, and then accruing subjects. Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA042777-20
Application #
7191922
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-01-21
Project End
2009-12-31
Budget Start
2007-05-25
Budget End
2007-12-31
Support Year
20
Fiscal Year
2007
Total Cost
$82,102
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7

Showing the most recent 10 out of 222 publications